Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T 1501

Next Previous
Drug Profile

T 1501

Alternative Names: DBPR-186; T-1501

Latest Information Update: 27 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Health Research Institutes
  • Developer Taivex Therapeutics
  • Class Amines; Antineoplastics; Drug conjugates; Maytansinoids; Small molecules; Zinc compounds
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Feb 2024 National Health Research Institutes files for patent protection with WIPO for T 1501 in USA, Taiwan, Japan, Australia, South Korea, New Zealand, India, the European Union and other countries worldwide prior to February 2024 (Taivex Therapeutics pipeline, February 2024).
  • 25 Apr 2023 Preclinical trials in Cancer in Taiwan (Parenteral) before April 2023 (Taivex Therapeutics pipeline, April 2023)
  • 01 Sep 2021 Taivex Therapeutics in-licenses T 1501 from the National Health Research Institutes

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top